Plain-English translation of NCT07658833 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing a combination approach to treat advanced liver cancer that cannot be surgically removed. Researchers are combining two types of minimally invasive procedures (where doctors deliver chemotherapy directly to the tumor through blood vessels) with medications like lenvatinib, sorafenib, or bevacizumab — which target cancer cells — along with immunotherapy drugs that boost your body's own immune system to fight the cancer. The goal is to see if the medication works safely and effectively when used together with these procedures.
Liver cancer is difficult to treat, especially when it's too large or extensive to remove surgically. Doctors want to know whether combining this medication with tumor-shrinking procedures — rather than using them separately — can help patients live longer and have better outcomes while managing side effects carefully.
You likely qualify if…
You likely don't qualify if…
You would receive specialized minimally invasive procedures where doctors deliver chemotherapy directly to your tumor through blood vessels in your liver, combined with the targeted and immune-boosting medications. You'll have regular clinic visits and imaging scans to monitor how your tumor is responding and to check for any side effects. The research team will carefully track your tumor's response, how long you survive, and any adverse events using standard medical criteria.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
China